Recent research indicates that PPAR-γ activators reduce extracellular matrix (ECM) deposition and mitigate myocardial fibrosis, while the PPAR-γ antagonist GW9662 reverses these protective effects (Lu et al., 2021). The gene discussed is PPARG; the disease is Myocardial fibrosis.